Share your experience validating the SARS-CoV-2 IgG Antibody assay1
Thank you for taking the time to provide feedback on the first semi-quantitative SARS-CoV-2 antibody assay to be granted Emergency Use Authorization by the FDA. We are interested in learning as much as possible about the experience of laboratorians who validate this assay.
Participants who complete the questionnaire below can receive 50% off their first ordered kit of SARS-CoV-2 IgG assay reagent and consumables. Once you have completed the survey, a Siemens Healthineers representative will be in touch with you with confirmation of your eligibility for this offer.
Did this information help you?
This test has not been FDA cleared or approved. This test has been authorized by FDA under an EUA for use by authorized laboratories. This test has been authorized only for detecting the presence of antibodies against SARS-CoV-2, not for any other viruses or pathogens. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Product availability may vary by country and is subject to regulatory requirements.